CL2019000043A1 - Nuevos análogos de urocortina-2 modificados con ácido graso para el tratamiento de diabetes y enfermedad renal crónica. - Google Patents
Nuevos análogos de urocortina-2 modificados con ácido graso para el tratamiento de diabetes y enfermedad renal crónica.Info
- Publication number
- CL2019000043A1 CL2019000043A1 CL2019000043A CL2019000043A CL2019000043A1 CL 2019000043 A1 CL2019000043 A1 CL 2019000043A1 CL 2019000043 A CL2019000043 A CL 2019000043A CL 2019000043 A CL2019000043 A CL 2019000043A CL 2019000043 A1 CL2019000043 A1 CL 2019000043A1
- Authority
- CL
- Chile
- Prior art keywords
- etoxi
- modified
- fatty acid
- amino
- urocortin
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/57509—Corticotropin releasing factor [CRF] (Urotensin)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2228—Corticotropin releasing factor [CRF] (Urotensin)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
Abstract
LA PRESENTE INVENCIÓN PROPORCIONA UN COMPUESTO O UNA SAL FARMACÉUTICAMENTE ACEPTABLE DE LA FÓRMULA: X1 I V X2 S L D V P I G L L Q I L X3 E Q E K Q E K E K Q Q A K* T N A X4 I L A Q V-NH2 EN DONDE EL X1 INDICA QUE EL RESIDUO I ES MODIFICADO YA SEA POR ACETILACIÓN O METILACIÓN EN EL EXTREMO N-TERMINAL; EN DONDE X2 ES L O T; EN DONDE X3 ES L O I; EN DONDE X4 ES Q O E; Y EN DONDE UN RESIDUO K MODIFICADO (“K*”) EN LA POSICIÓN 29 ES MODIFICADO A TRAVÉS DE LA CONJUGACIÓN AL GRUPO EPSILÓN-AMINO DE LA CADENA LATERAL K CON UN GRUPO DE LA FÓRMULA –X5–X6, EN DONDE X5 SE SELECCIONA DEL GRUPO QUE CONSISTE DE UNO A CUATRO AMINOÁCIDOS; UNA A CUATRO PORCIONES DE ([2-(2-AMINO-ETOXI)-ETOXI]-ACETIL); Y COMBINACIONES DE UNO A CUATRO AMINOÁCIDOS Y UNA A CUATRO PORCIONES DE ([2-(2-AMINO-ETOXI)-ETOXI]-ACETIL); Y X6 ES UN ÁCIDO GRASO DE C14-C24. EN ALGUNAS MODALIDADES, EL GRUPO DE LA FÓRMULA –X5–X6 ES ([2-(2-AMINO-ETOXI)-ETOXI]-ACETIL)2-(?E)2-CO-(CH2)X-CO2H DONDE X ES 16 O 18.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662362711P | 2016-07-15 | 2016-07-15 | |
| US201662431682P | 2016-12-08 | 2016-12-08 | |
| US201762491385P | 2017-04-28 | 2017-04-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2019000043A1 true CL2019000043A1 (es) | 2019-06-07 |
Family
ID=59501524
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2019000043A CL2019000043A1 (es) | 2016-07-15 | 2019-01-07 | Nuevos análogos de urocortina-2 modificados con ácido graso para el tratamiento de diabetes y enfermedad renal crónica. |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US10894817B2 (es) |
| EP (1) | EP3484495B1 (es) |
| JP (1) | JP2019525919A (es) |
| KR (1) | KR20190017982A (es) |
| CN (1) | CN109475592B (es) |
| AU (1) | AU2017295708B2 (es) |
| BR (1) | BR112018076693A2 (es) |
| CA (1) | CA3030965C (es) |
| CL (1) | CL2019000043A1 (es) |
| CO (1) | CO2018014026A2 (es) |
| CR (1) | CR20190015A (es) |
| DO (1) | DOP2019000007A (es) |
| EC (1) | ECSP19003047A (es) |
| ES (1) | ES2901477T3 (es) |
| IL (1) | IL264025A (es) |
| JO (1) | JOP20170153A1 (es) |
| MA (1) | MA45673A (es) |
| MX (1) | MX2019000661A (es) |
| PE (1) | PE20190470A1 (es) |
| PH (1) | PH12019500074A1 (es) |
| SG (1) | SG11201811737SA (es) |
| SV (1) | SV2019005808A (es) |
| TW (1) | TW201811821A (es) |
| WO (1) | WO2018013803A1 (es) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10844069B2 (en) | 2016-03-28 | 2020-11-24 | Incyte Corporation | Pyrrolotriazine compounds as TAM inhibitors |
| US11104682B2 (en) | 2017-09-27 | 2021-08-31 | Incyte Corporation | Salts of TAM inhibitors |
| US11136326B2 (en) | 2015-08-26 | 2021-10-05 | Incyte Corporation | Pyrrolopyrimidine derivatives as TAM inhibitors |
| US11918585B2 (en) | 2018-06-29 | 2024-03-05 | Incyte Corporation | Formulations of an AXL/MER inhibitor |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019140021A1 (en) * | 2018-01-12 | 2019-07-18 | Eli Lilly And Company | Combination therapy |
| WO2019140024A1 (en) * | 2018-01-12 | 2019-07-18 | Eli Lilly And Company | Combination therapy |
| WO2019140023A1 (en) * | 2018-01-12 | 2019-07-18 | Eli Lilly And Company | Combination therapy |
| WO2019140025A1 (en) * | 2018-01-12 | 2019-07-18 | Eli Lilly And Company | Combination therapy |
| WO2019140030A1 (en) * | 2018-01-12 | 2019-07-18 | Eli Lilly And Company | Combination therapy |
| US20200027555A1 (en) * | 2018-07-17 | 2020-01-23 | Lewis Pharmaceutical Information, Inc. | Patient centric drug analysis platform |
| AU2021328673A1 (en) | 2020-08-19 | 2023-03-30 | Sanofi | CRF2 receptor agonists and their use in therapy |
| WO2022159395A1 (en) | 2021-01-20 | 2022-07-28 | Viking Therapeutics, Inc. | Compositions and methods for the treatment of metabolic and liver disorders |
| WO2023285334A1 (en) * | 2021-07-12 | 2023-01-19 | Novo Nordisk A/S | Novel fatty acid modified urocortin 2 derivatives and the uses thereof |
| EP4234574A1 (en) | 2022-02-23 | 2023-08-30 | Corteria Pharmaceuticals | Crf2 receptor agonists and their use in therapy |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0724637B2 (en) | 1994-06-14 | 2002-06-05 | Neurocrine Biosciences, Inc. | Corticotropin-releasing factor 2 receptors |
| EP0845035A2 (en) | 1995-06-13 | 1998-06-03 | The Salk Institute For Biological Studies | Urocortin peptides |
| US20040034882A1 (en) | 1999-07-15 | 2004-02-19 | Vale Wylie W. | Corticotropin releasing factor receptor 2 deficient mice and uses thereof |
| IL154102A0 (en) | 2000-08-04 | 2003-07-31 | Res Dev Foundation | Urocortin proteins and uses thereof |
| US20020082409A1 (en) | 2000-10-26 | 2002-06-27 | Hsu Sheau Yu | Stresscopins and their uses |
| IL154553A0 (en) | 2001-03-15 | 2003-09-17 | Res Dev Foundation | Urocortin-iii and uses thereof |
| US6936585B2 (en) * | 2002-01-16 | 2005-08-30 | The Procter & Gamble Company | Corticotropin releasing factor 2 receptor agonists |
| GR1004664B (en) | 2002-11-26 | 2004-09-02 | Bionature E A Ltd | The charakteristics and advantages of our invention are illustrated by the following description, methods and results of our research, attached figures and supporting references |
| WO2005103690A2 (en) | 2004-04-24 | 2005-11-03 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with corticotropin releasing hormone receptor 2 (crhr2) |
| US7869958B2 (en) | 2004-08-09 | 2011-01-11 | Research Development Foundation | Structure-based modulators of B1 G-protein coupled receptors |
| KR20070112155A (ko) | 2005-02-08 | 2007-11-22 | 리서치 디벨럽먼트 파운데이션 | 가용성 Ｇ-단백질 연결 수용체(ｓＧＰＣＲ)와 관련된조성물 및 방법 |
| US7815905B2 (en) | 2006-01-27 | 2010-10-19 | Research Development Foundation | Methods of increasing insulin sensitivity or decreasing insulin secretion by administering corticotropin releasing factor receptor-2 inhibitors |
| WO2008047241A2 (en) * | 2006-10-16 | 2008-04-24 | Conjuchem Biotechnologies Inc. | Modified corticotropin releasing factor peptides and uses thereof |
| WO2008157302A2 (en) | 2007-06-13 | 2008-12-24 | Research Development Foundation | Methods for treatment and prevention of tauopathies and amyloid beta amyloidosis by modulating crf receptor signaling |
| CA2742710A1 (en) * | 2008-11-04 | 2010-05-14 | Janssen Pharmaceutica Nv | Crhr2 peptide agonists and uses thereof |
| US20120238509A1 (en) | 2009-08-28 | 2012-09-20 | Research Development Foundation | Urocortin 2 analogs and uses thereof |
| EP2496248A2 (en) | 2009-11-04 | 2012-09-12 | Janssen Pharmaceutica, N.V. | Method for treating heart failure with stresscopin-like peptides |
| WO2011092293A2 (en) | 2010-02-01 | 2011-08-04 | Novartis Ag | Cyclohexyl amide derivatives as crf receptor antagonists |
| JP5748777B2 (ja) | 2010-02-02 | 2015-07-15 | ノバルティス アーゲー | Ｃｒｆ受容体アンタゴニストとしてのシクロヘキシルアミド誘導体 |
| WO2013063046A1 (en) | 2011-10-24 | 2013-05-02 | Research Development Foundation | Methods for increasing insulin secretion by co-stimulation of corticotropin-releasing factor receptors |
| US20170182129A1 (en) | 2014-04-03 | 2017-06-29 | The Regents Of The University Of California | Systemic delivery of virus vectors encoding urocortin-2 and related genes to treat diabetes-related cardiac dysfunctions and congestive heart failure |
| AR104932A1 (es) * | 2015-06-22 | 2017-08-23 | Lilly Co Eli | Compuestos co-agonistas del glucagón y péptido-1 similar al glugacón (glp-1) |
| WO2017220706A1 (en) * | 2016-06-22 | 2017-12-28 | Novo Nordisk A/S | Pharmaceutical compositions of fgf21 derivatives and uses thereof |
-
2016
- 2016-07-15 JO JOP/2017/0153A patent/JOP20170153A1/ar unknown
-
2017
- 2017-06-30 TW TW106121914A patent/TW201811821A/zh unknown
- 2017-07-13 CR CR20190015A patent/CR20190015A/es unknown
- 2017-07-13 AU AU2017295708A patent/AU2017295708B2/en not_active Ceased
- 2017-07-13 CN CN201780043923.7A patent/CN109475592B/zh active Active
- 2017-07-13 ES ES17746231T patent/ES2901477T3/es active Active
- 2017-07-13 BR BR112018076693-3A patent/BR112018076693A2/pt not_active Application Discontinuation
- 2017-07-13 CA CA3030965A patent/CA3030965C/en active Active
- 2017-07-13 EP EP17746231.4A patent/EP3484495B1/en active Active
- 2017-07-13 JP JP2019501685A patent/JP2019525919A/ja not_active Withdrawn
- 2017-07-13 WO PCT/US2017/041922 patent/WO2018013803A1/en unknown
- 2017-07-13 KR KR1020197001249A patent/KR20190017982A/ko not_active Application Discontinuation
- 2017-07-13 MX MX2019000661A patent/MX2019000661A/es unknown
- 2017-07-13 US US15/648,542 patent/US10894817B2/en active Active
- 2017-07-13 MA MA045673A patent/MA45673A/fr unknown
- 2017-07-13 PE PE2019000060A patent/PE20190470A1/es unknown
- 2017-07-13 SG SG11201811737SA patent/SG11201811737SA/en unknown
-
2018
- 2018-12-21 CO CONC2018/0014026A patent/CO2018014026A2/es unknown
- 2018-12-30 IL IL264025A patent/IL264025A/en unknown
-
2019
- 2019-01-07 CL CL2019000043A patent/CL2019000043A1/es unknown
- 2019-01-10 DO DO2019000007A patent/DOP2019000007A/es unknown
- 2019-01-11 SV SV2019005808A patent/SV2019005808A/es unknown
- 2019-01-11 PH PH12019500074A patent/PH12019500074A1/en unknown
- 2019-01-15 EC ECSENADI20193047A patent/ECSP19003047A/es unknown
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11136326B2 (en) | 2015-08-26 | 2021-10-05 | Incyte Corporation | Pyrrolopyrimidine derivatives as TAM inhibitors |
| US10844069B2 (en) | 2016-03-28 | 2020-11-24 | Incyte Corporation | Pyrrolotriazine compounds as TAM inhibitors |
| US11591338B2 (en) | 2016-03-28 | 2023-02-28 | Incyte Corporation | Pyrrolotriazine compounds as TAM inhibitors |
| US11104682B2 (en) | 2017-09-27 | 2021-08-31 | Incyte Corporation | Salts of TAM inhibitors |
| US11918585B2 (en) | 2018-06-29 | 2024-03-05 | Incyte Corporation | Formulations of an AXL/MER inhibitor |
Also Published As
| Publication number | Publication date |
|---|---|
| CA3030965A1 (en) | 2018-01-18 |
| PE20190470A1 (es) | 2019-04-04 |
| CN109475592A (zh) | 2019-03-15 |
| TW201811821A (zh) | 2018-04-01 |
| SV2019005808A (es) | 2019-04-04 |
| EP3484495A1 (en) | 2019-05-22 |
| DOP2019000007A (es) | 2019-04-15 |
| WO2018013803A1 (en) | 2018-01-18 |
| ECSP19003047A (es) | 2019-01-31 |
| SG11201811737SA (en) | 2019-01-30 |
| ES2901477T3 (es) | 2022-03-22 |
| CA3030965C (en) | 2022-04-26 |
| CN109475592B (zh) | 2022-08-09 |
| EP3484495B1 (en) | 2021-09-08 |
| JP2019525919A (ja) | 2019-09-12 |
| US10894817B2 (en) | 2021-01-19 |
| PH12019500074A1 (en) | 2019-07-29 |
| AU2017295708B2 (en) | 2019-05-09 |
| AU2017295708A1 (en) | 2018-12-20 |
| IL264025A (en) | 2019-01-31 |
| CR20190015A (es) | 2019-02-27 |
| MA45673A (fr) | 2021-05-26 |
| KR20190017982A (ko) | 2019-02-20 |
| CO2018014026A2 (es) | 2019-01-18 |
| MX2019000661A (es) | 2019-05-15 |
| US20180016318A1 (en) | 2018-01-18 |
| BR112018076693A2 (pt) | 2019-04-02 |
| JOP20170153A1 (ar) | 2019-01-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2019000043A1 (es) | Nuevos análogos de urocortina-2 modificados con ácido graso para el tratamiento de diabetes y enfermedad renal crónica. | |
| HRP20191614T1 (hr) | Spojevi koji su suagonisti gip i glp-1 | |
| ES2606173T3 (es) | Composición farmacéutica para el tratamiento y/o la prevención del cáncer | |
| CL2020002026A1 (es) | Inhibidor de fap. | |
| EA201590525A1 (ru) | Слитые белки для лечения метаболического синдрома | |
| PE20120586A1 (es) | Proteinas de union a il-1 | |
| PE20170665A1 (es) | Anticuerpos anti-tau humanizados | |
| AR117913A2 (es) | Conjugado fármaco-anticuerpo, composición farmacéutica y sus usos | |
| EA033387B1 (ru) | СТАБИЛИЗИРОВАННЫЕ СОСТАВЫ, СОДЕРЖАЩИЕ АНТИТЕЛА ПРОТИВ Ang-2 | |
| BR112014009790A2 (pt) | composto para modulação antisense da expressão de gccr, seu uso e composição | |
| ES2531083T3 (es) | Formulaciones estables de polipéptidos y usos de las mismas | |
| NZ629204A (en) | Anti-vla1 (cd49a) antibody pharmaceutical compositions | |
| PE20141413A1 (es) | Formulaciones de anticuerpo y metodos | |
| DOP2011000204A (es) | Inhibidores de proteina cinasa | |
| CL2017003097A1 (es) | Composiciones y métodos para el tratamiento de la enfermedad celiaca | |
| AR067555A1 (es) | Derivado de peptido insulinotropico en el cual se modifica su aminoacido n- terminal | |
| AR086074A1 (es) | Composiciones y metodo para tratar enfermedades autoinmunes | |
| PE20141151A1 (es) | Proteinas de union al antigeno cd27l | |
| AR083034A1 (es) | ESTABILIZACION DE INMUNOGLOBULINAS Y OTRAS PROTEINAS MEDIANTE UNA FORMULACION ACUOSA CON CLORURO DE SODIO A pH ACIDO DEBIL A NEUTRO | |
| PE20141473A1 (es) | Senalizacion slit-robo para el diagnostico y tratamiento de la enfermedad renal | |
| BR112016029476A2 (pt) | complexos de aminoácido mineral de agentes ativos | |
| AR102595A1 (es) | Anticuerpos anti-ang2 y métodos de utilización | |
| UA108778C2 (xx) | Протираковий злитий протеїн | |
| EA201390820A1 (ru) | Слитый белок против рака | |
| BR112016015701A2 (pt) | Dendrímero de peptídeo, método de esterilização do mesmo, composição, composição farmacêutica, método de polimerização de fibrinogênio, kit para formação de um hidrogel e hidrogel |